Halozyme Therapeutics Inc
HALO
NASDAQ
Biotechnology
$98.66
USD
-2.01 (-2.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $11.43B
Volume 1.7M
Revenue
$1.66B
TTM
+41.2%
YoY
Gross Margin
82%
TTM
-2.1%
YoY
Net Income
$413.60M
TTM
-25.8%
YoY
Operating Cash Flow
$818.60M
TTM
+49.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 325.7 | 354.3 | 451.8 | 376.7 | 481.0 |
YoY Growth | +40.8% | +22.1% | +51.6% | +42.2% | +47.7% |
Cost of Revenue | 46.4 | 55.2 | 78.8 | 79.2 | 79.2 |
Gross Profit | 279.4 | 299.0 | 373.0 | 297.5 | 401.8 |
Selling, General & Administrative | 41.6 | 46.1 | 77.0 | 57.9 | 57.0 |
Other Operating Expenses | 0.0 | 0.0 | 284.9 | 0.0 | 0.0 |
Total Operating Expenses | 76.9 | 81.1 | 417.2 | 113.0 | 114.2 |
Operating Income | 202.4 | 217.9 | -44.2 | 184.5 | 287.7 |
EBITDA | 222.9 | 238.3 | 267.4 | 218.3 | 321.6 |
Other Income / Expense | 0.0 | 5.3 | -51.7 | 1.3 | 0.0 |
Total Other Income / Expense | 2.5 | 1.0 | -56.7 | -4.2 | -2.8 |
Income Before Income Taxes | 204.9 | 219.0 | -100.8 | 180.3 | 284.9 |
Income Taxes | 39.8 | 43.7 | 40.7 | 30.3 | 55.0 |
Net Income | 165.2 | 175.2 | -141.6 | 150.0 | 229.9 |
Consolidated Net Income / Loss | 165.2 | 175.2 | -141.6 | 150.0 | 229.9 |
Net Income Attributable to Common Shareholders | 165.2 | 175.2 | -141.6 | 150.0 | 229.9 |
Basic EPS | $1.36 | $1.49 | -$1.20 | $1.27 | $1.96 |
Diluted EPS | $1.33 | $1.43 | -$1.16 | $1.22 | $1.90 |
Basic Shares Outstanding | 121.3M | 117.2M | 117.6M | 118.1M | 117.3M |
Diluted Shares Outstanding | 124.2M | 122.3M | 122.5M | 122.9M | 121.2M |